Reinhard Dummer Selected Research

SOXE Transcription Factors

1/2020	Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.
1/2015	Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Reinhard Dummer Research Topics

Disease

281	Melanoma (Melanoma, Malignant) 10/2022 - 03/2002
197	Neoplasms (Cancer) 01/2022 - 01/2002
50	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2002
29	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 12/2021 - 03/2002
25	Basal Cell Carcinoma (Rodent Ulcer) 05/2022 - 10/2003
19	Lymphoma (Lymphomas) 01/2020 - 01/2002
18	Disease Progression 01/2022 - 01/2004
16	Brain Neoplasms (Brain Tumor) 10/2021 - 02/2008
14	Skin Neoplasms (Skin Cancer) 03/2020 - 01/2002
11	Mycosis Fungoides 12/2021 - 01/2003
11	Carcinogenesis 01/2021 - 08/2004
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 08/2008
9	Exanthema (Rash) 01/2021 - 06/2011
7	Colitis 08/2020 - 05/2015
7	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 01/2002
6	Inflammation (Inflammations) 01/2022 - 01/2009
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 05/2004
6	Testicular Neoplasms (Testicular Cancer) 10/2020 - 01/2007
6	Lymphatic Metastasis 01/2019 - 08/2003
6	Neutropenia 11/2018 - 09/2008
6	Fatigue 09/2017 - 07/2008
6	Dermatitis 11/2016 - 09/2011
5	Pain (Aches) 12/2021 - 03/2002
5	Fever (Fevers) 01/2021 - 03/2002
4	Alopecia (Baldness) 01/2020 - 06/2011
4	Wounds and Injuries (Trauma) 01/2020 - 12/2011
4	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020 - 03/2004
4	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2018 - 12/2004
4	Myalgia 10/2018 - 04/2014
4	Arthralgia (Joint Pain) 10/2018 - 06/2011
4	Nausea 01/2018 - 06/2011
4	Keratoacanthoma 01/2015 - 04/2011
4	Pigmented Nevus (Melanocytic Nevus) 01/2014 - 04/2004
4	Diarrhea 07/2012 - 06/2011

Drug/Important Bio-Agent (IBA)

47	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 12/2009
40	IpilimumabIBA 10/2022 - 01/2013
35	Immune Checkpoint InhibitorsIBA 07/2022 - 06/2017
34	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
26	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2006
23	pembrolizumabIBA 06/2022 - 08/2015
21	InterferonsIBA 01/2022 - 03/2002
21	VemurafenibIBA 01/2020 - 06/2011
20	NivolumabIBA 10/2022 - 07/2015
20	AntigensIBA 10/2020 - 01/2002
18	Pharmaceutical PreparationsIBA 04/2022 - 03/2002
17	trametinibIBA 01/2022 - 07/2012
16	binimetinibIBA 06/2022 - 03/2013
16	dabrafenibIBA 01/2022 - 01/2015
16	Phosphotransferases (Kinase)IBA 01/2022 - 12/2009
16	Dacarbazine (DIC)FDA LinkGeneric 01/2021 - 12/2005
15	CytokinesIBA 01/2022 - 03/2002
14	AntibodiesIBA 12/2020 - 09/2002
13	encorafenibIBA 06/2022 - 01/2015
13	LigandsIBA 01/2022 - 03/2002
12	sonidegibIBA 05/2022 - 04/2014
12	Imiquimod (Aldara)FDA LinkGeneric 12/2018 - 01/2003
11	Peptides (Polypeptides)IBA 12/2021 - 05/2002
10	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2003
10	Mitogen-Activated Protein KinasesIBA 03/2019 - 12/2009
9	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2002
9	Interleukin-2 (IL2)IBA 09/2019 - 03/2002
8	Messenger RNA (mRNA)IBA 01/2022 - 03/2002
8	Formaldehyde (Formol)FDA Link 01/2021 - 04/2004
8	MART-1 AntigenIBA 01/2019 - 01/2004
7	Monoclonal AntibodiesIBA 01/2020 - 04/2004
7	Monophenol Monooxygenase (Tyrosinase)IBA 01/2019 - 01/2004
7	Interferon-alpha (Interferon Alfa)IBA 08/2012 - 08/2003
6	HhAntag691IBA 05/2022 - 06/2015
6	Bexarotene (LGD1069)FDA Link 12/2021 - 08/2006
6	Biological ProductsIBA 01/2021 - 01/2002
6	Temozolomide (Temodar)FDA LinkGeneric 01/2018 - 12/2005
6	OligonucleotidesIBA 11/2012 - 03/2002
6	HLA-G Antigens (HLA G)IBA 02/2008 - 01/2002
5	Programmed Cell Death 1 ReceptorIBA 01/2022 - 09/2015
5	Brentuximab VedotinIBA 12/2021 - 01/2015
5	Adapalene (Differin)FDA LinkGeneric 12/2021 - 04/2011
5	EnzymesIBA 01/2021 - 07/2005
5	talimogene laherparepvecIBA 01/2021 - 01/2017
5	ParaffinIBA 01/2021 - 04/2004
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 12/2007
5	Differentiation AntigensIBA 08/2020 - 12/2006
5	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020 - 03/2002
5	Creatine Kinase (Creatine Phosphokinase)IBA 01/2019 - 03/2013
5	Proto-Oncogene Proteins B-rafIBA 01/2018 - 06/2011
5	Interleukin-10 (Interleukin 10)IBA 01/2016 - 01/2002
4	MicroRNAs (MicroRNA)IBA 01/2022 - 11/2019
4	Glycoproteins (Glycoprotein)IBA 01/2021 - 05/2013
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 07/2004
4	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 01/2019 - 02/2010
4	AZD 6244IBA 07/2013 - 12/2009
4	VaccinesIBA 05/2013 - 11/2006
4	Toll-Like Receptor 7IBA 01/2013 - 12/2004

Therapy/Procedure

166	Therapeutics 06/2022 - 01/2002
61	Immunotherapy 06/2022 - 01/2002
24	Drug Therapy (Chemotherapy) 01/2022 - 03/2002
20	Radiotherapy 01/2022 - 12/2003
11	Aftercare (After-Treatment) 06/2021 - 10/2003
7	Lasers (Laser) 01/2020 - 11/2003
4	Precision Medicine 01/2021 - 03/2014
4	Lymph Node Excision (Lymph Node Dissection) 11/2017 - 02/2008